Evidence map›Paper›PMID 33676420›Full record

ArticleBMC infectious diseases2021

Evaluating the effectiveness of measures to control the novel coronavirus disease 2019 in Jilin Province, China.

Qinglong Zhao, Yao Wang, Meng Yang, Meina Li, Zeyu Zhao, Xinrong Lu, Bo Shen, Bo Luan, Yifei Zhao, Bonan Cao and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. ComputingInfectious Disease Modelling · 2022
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Qinglong Zhao *Jilin Provincial Center for Disease Control and Prevention, Changchun, Jilin Province, 130062, People's Republic of China.
Yao Wang *State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, Fujian Province, 361102, People's Republic of China.
Meng Yang *State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, Fujian Province, 361102, People's Republic of China.
Meina LiThe First Hospital of Jilin University, Changchun, Jilin Province, 130021, People's Republic of China.
Zeyu ZhaoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, Fujian Province, 361102, People's Republic of China.
Xinrong LuJilin Provincial Center for Disease Control and Prevention, Changchun, Jilin Province, 130062, People's Republic of China.
Bo ShenJilin Provincial Center for Disease Control and Prevention, Changchun, Jilin Province, 130062, People's Republic of China.
Bo LuanJilin Provincial Center for Disease Control and Prevention, Changchun, Jilin Province, 130062, People's Republic of China.
Yifei ZhaoJilin Provincial Center for Disease Control and Prevention, Changchun, Jilin Province, 130062, People's Republic of China.
Bonan CaoJilin Provincial Center for Disease Control and Prevention, Changchun, Jilin Province, 130062, People's Republic of China.
Laishun YaoJilin Provincial Center for Disease Control and Prevention, Changchun, Jilin Province, 130062, People's Republic of China.
Benhua ZhaoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, Fujian Province, 361102, People's Republic of China.
Yanhua SuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, Fujian Province, 361102, People's Republic of China. suyanhua813@xmu.edu.cn.
Tianmu ChenState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, Fujian Province, 361102, People's Republic of China. chentianmu@xmu.edu.cn.ORCID http://orcid.org/0000-0003-0710-5086
Health Commission of Jilin Province · CNXiamen University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBased on differences in populations and prevention and control measures, the spread of new coronary pneumonia in different countries and regions also differs. This study aimed to calculate the transmissibility of coronavirus disease 2019 (COVID-19), and to evaluate the effectiveness of measures to control the disease in Jilin Province, China.

methodsThe data of reported COVID-19 cases were collected, including imported and local cases from Jilin Province as of March 14, 2019. A Susceptible-Exposed-Infectious-Asymptomatic-Recovered/Removed (SEIAR) model was developed to fit the data, and the effective reproduction number (R

resultsA total of 97 COVID-19 infections were reported in Jilin Province, among which 45 were imported infections (including one asymptomatic infection) and 52 were local infections (including three asymptomatic infections). The model fit the reported data well (R

conclusionsCOVID-19 has a moderate transmissibility in Jilin Province, China. The interventions implemented in the province had proven effective; increasing social distancing and a rapid response by the prevention and control system will help control the spread of the disease.

Indexed as

Basic Reproduction NumberCommunicable Disease ControlCOVID-19ChinaHumansIncidenceOutcome Assessment, Health CareSARS-CoV-2COVID-19EpidemicMeasuresTransmissibility

Identifiers

PMID33676420
PMCPMC7936873
OpenAlexW3112826292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.